| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
We conducted a quasi-experimental study to compare the response to meglumine antimoniate in patients with localized cutaneous leishmaniasis from two endemic areas of Brazil that were infected by two Leishmania species. Sixty-one were infected by Leishmania (Viannia) braziliensis (group B) and 57 by L. (V.) guyanensis (group G). All had a parasitologically proven diagnosis and were treated with 20 mg of pentavalent antimonial (SbV)/kg/day given intravenously or intramuscularly for 20 days. Main outcomes were diagnosed using clinical criteria three months after treatment and patients were followed for six months. Intention-to-treat analysis showed a higher failure rate in group G (relative risk [RR] = 1.5, 95% confidence interval [CI] = 1.1-2.0, chi2 = 7.44, P = 0.006). The analysis using an explanatory approach including 52 patients from group B and 49 from group G, who were regularly treated and followed for six months, showed a low cure rate (50.8% in group B and 26.3% in group G) with a greater risk of failure in the latter group (RR = 1.7, 95% CI = 1.2-2.5, chi2 = 8.56, P = 0.003). The effect of the etiologic agent remained significant after adjusting for age, disease duration, and site and number of lesions that were identified as predictors of failure in a logistic regression model. We concluded that Leishmania species constitute an important factor in predicting the outcome of cutaneous leishmaniasis treated with a pentavalent antimonial.
This article has been cited by other articles:
|
|
 |
|
  I. Rodriguez-Barraquer, R. Gongora, M. Prager, R. Pacheco, L. M. Montero, A. Navas, C. Ferro, M. C. Miranda, and N. G. Saravia Etiologic Agent of an Epidemic of Cutaneous Leishmaniasis in Tolima, Colombia Am J Trop Med Hyg, February 1, 2008; 78(2): 276 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Castilho, L. M. A. Camargo, D. McMahon-Pratt, J. J. Shaw, and L. M. Floeter-Winter A Real-Time Polymerase Chain Reaction Assay for the Identification and Quantification of American Leishmania Species on the Basis of Glucose-6-Phosphate Dehydrogenase Am J Trop Med Hyg, January 1, 2008; 78(1): 122 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Layegh, M. J. Yazdanpanah, E. M. Vosugh, F. Pezeshkpoor, M. T. Shakeri, and T. Moghiman Efficacy of Azithromycin versus Systemic Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis Am J Trop Med Hyg, July 1, 2007; 77(1): 99 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. MARCO, H. UEZATO, T. MIMORI, P. A. BARROSO, M. KORENAGA, S. NONAKA, M. A. BASOMBRIO, N. J. TARANTO, and Y. HASHIGUCHI ARE CYTOCHROME B GENE SEQUENCING AND POLYMORPHISM-SPECIFIC POLYMERASE CHAIN REACTION AS RELIABLE AS MULTILOCUS ENZYME ELECTROPHORESIS FOR IDENTIFYING LEISHMANIA SPP. FROM ARGENTINA? Am J Trop Med Hyg, August 1, 2006; 75(2): 256 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. ZELAZNY, D. P. FEDORKO, L. LI, F. A. NEVA, and S. H. FISCHER EVALUATION OF 7SL RNA GENE SEQUENCES FOR THE IDENTIFICATION OF LEISHMANIA SPP. Am J Trop Med Hyg, April 1, 2005; 72(4): 415 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. SOTO, J. TOLEDO, J. VEGA, and J. BERMAN SHORT REPORT: EFFICACY OF PENTAVALENT ANTIMONY FOR TREATMENT OF COLOMBIAN CUTANEOUS LEISHMANIASIS Am J Trop Med Hyg, April 1, 2005; 72(4): 421 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Blum, P. Desjeux, E. Schwartz, B. Beck, and C. Hatz Treatment of cutaneous leishmaniasis among travellers J. Antimicrob. Chemother., February 1, 2004; 53(2): 158 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Castilho, J. J. Shaw, and L. M. Floeter-Winter New PCR Assay Using Glucose-6-Phosphate Dehydrogenase for Identification of Leishmania Species J. Clin. Microbiol., February 1, 2003; 41(2): 540 - 546. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
